Biliary Tract Cancers, version 2.2025: NCCN Clinical Practice Guidelines In Oncology Guidelines


Authors: Benson, A. B. 3rd; D'Angelica, M. I.; Abrams, T.; Ahmed, A.; Akce, M.; Anaya, D. A.; Anders, R.; Are, C.; Aye, L.; Bachini, M.; Baker, M.; Binder, D.; Brown, D. B.; Burgoyne, A.; Castellanos, J.; Cloyd, J.; Cullinan, D.; Franses, J.; Glazer, E. S.; Harris, W.; Iyer, R.; Jennings, L.; Kelley, R. K.; Khan, S.; Levine, M.; Melstrom, L.; Palta, M.; Raman, S.; Ronnekleiv-Kelly, S.; Sahai, V.; Stein, S.; Stephans, K.; Thanikachalam, K.; Turk, A.; Vauthey, J. N.; Venook, A. P.; Yano, M.; Yopp, A.; Zhao, K.; Schonfeld, R.; Hochstetler, C.
Title: Biliary Tract Cancers, version 2.2025: NCCN Clinical Practice Guidelines In Oncology
Abstract: <p>The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.</p>
Keywords: gallbladder carcinoma; phase-ii trial; hepatocellular-carcinoma; beam radiation-therapy; open-label; extrahepatic cholangiocarcinoma; 1st-line chemotherapy; capecitabine plus oxaliplatin; gall-bladder cancer; positive solid tumors
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 23
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2025-09-01
Start Page: 403
End Page: 418
Language: English
ACCESSION: WOS:001571933800015
DOI: 10.6004/jnccn.2025.0042
PROVIDER: wos
PUBMED: 40930144
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ken Zhao
    41 Zhao